Reuters logo
BRIEF-Genmab and Seattle Genetics to start study of Tisotumab Vedotin in cervical cancer
October 10, 2017 / 10:24 AM / in 13 days

BRIEF-Genmab and Seattle Genetics to start study of Tisotumab Vedotin in cervical cancer

Oct 10 (Reuters) - GENMAB A/S

* GENMAB AND SEATTLE GENETICS TO INITIATE NEW STUDY OF NOVEL ANTIBODY-DRUG CONJUGATE TISOTUMAB VEDOTIN IN CERVICAL CANCER

* SAYS ‍STUDY COULD PROVIDE BASIS FOR A REGULATORY APPLICATION FOR APPROVAL​

* ‍COMPANIES PLAN TO START ENROLLING PATIENTS BY FIRST HALF OF 2018.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below